# Q3-2026 Week 2 Checkpoint (July 15, 2026)
## Mid-Execution Status & FDA Assessment Progress

**Report Date:** July 15, 2026  
**Period:** July 8–15 (Weeks 1-2 of Q3)  
**Status:** ✅ ON SCHEDULE — All initiatives green; critical milestones achieved

---

## Executive Summary

Q3 Week 2 checkpoint shows all 5 initiatives on schedule with critical milestones achieved:
- ✅ FMEA baseline workshop completed (18 hazard modes identified)
- ✅ Tempo deployed to production (trace storage live)
- ✅ EHR mapping specification 50% complete
- ✅ FDA technical assessment phase 1 complete

**Overall Progress:** 35% complete (26 of 74 hours consumed)

---

## Initiative Status Updates

### Q3-1: ISO 14971 FMEA Formalization — 50% COMPLETE

**Week 2 Deliverables:**
- ✅ Risk analysis workshop completed (Jul 8, 2 hours)
  - Attendees: Compliance Officer, Clinical Advisor, Engineering Lead, Product Manager
  - Outcomes: 18 hazard modes identified, initial scoring completed
- ✅ FMEA baseline spreadsheet 50% documented
- ✅ Mitigation strategies drafted for 8 high/medium-risk modes

**Hazard Modes Identified (18 Total):**

| Category | Modes | Examples | Risk Level |
|----------|-------|----------|-----------|
| Calculation/Algorithm | 5 | Percentile error, CDS logic error, precision loss | Medium-High |
| Data Integrity | 5 | Data corruption, missing fields, concurrent write conflict | Medium-Low |
| System/Operational | 5 | Timeout, DB failure, version mismatch, backup failure | Low-Medium |
| Human/Interface | 3 | Misinterpretation, wrong patient selection, misleading format | High |

**High-Risk Modes (Require Mitigation):**
1. Clinician misinterprets output (Severity: High, Occurrence: Medium, RPN: High)
2. Wrong patient selected in UI (Severity: Critical, Occurrence: Low, RPN: High)
3. CDS algorithm logic error (Severity: High, Occurrence: Low, RPN: Medium)
4. EHR integration data mismatch (Severity: High, Occurrence: Low, RPN: Medium)

**Mitigation Strategies Drafted:**
- Mode 1: Clear labeling + clinical interpretation guide (verification: usability testing)
- Mode 2: Patient ID verification on every action (verification: unit tests >95% coverage)
- Mode 3: Algorithm validation against reference implementations (verification: 50+ regression test cases)
- Mode 4: Data mapping validation at integration points (verification: sandbox integration tests)

**Effort Consumed:** 8 hours (of 10 hour budget)

**Next Milestones:**
- Jul 22–28: FMEA documentation completion (2 hours remaining)
- Jul 28: FMEA baseline frozen for input to Q3-4 FDA assessment
- Quarterly review schedule: Aug 15, Nov 15, Feb 2027

---

### Q3-2: EHR Integration Framework — 36% COMPLETE

**Week 2 Deliverables:**
- ✅ FHIR mapping specification draft 50% complete (3 of 5 resource types mapped)
- ✅ Resource types mapped:
  1. **Patient** ↔ Internal patient model
     - FHIR fields: ID, name, DOB, gender, contact info, address
     - Mapping: 1:1 for identity fields; address requires parsing
     - Status: COMPLETE ✅
  2. **Observation** ↔ Growth metrics (height, weight, head circumference)
     - FHIR fields: Code (LOINC), value, effectiveDateTime, performer
     - Mapping: Measurements → Observation codes; timestamps aligned
     - Status: COMPLETE ✅
  3. **DiagnosticReport** ↔ Assessment results
     - FHIR fields: Subject, result (Observations), effective date, conclusion
     - Mapping: Test results → DiagnosticReport with references
     - Status: IN PROGRESS (70% complete)
- ✅ Sandbox testing continued
  - Epic sandbox: 15+ Patient queries, 12 Observation queries successful
  - Cerner sandbox: 10 Patient queries, 8 Observation queries successful
  - Performance: Epic avg 145ms, Cerner avg 203ms (acceptable)

**Mapping Specification Document Status:**
- ✅ Architecture section (data flow diagram, bidirectional sync strategy)
- ✅ Patient resource mapping (specification + code examples)
- ✅ Observation resource mapping (specification + transformation logic)
- ⏳ DiagnosticReport, DocumentReference, Encounter (in progress)

**Effort Consumed:** 8 hours (of 22 hour budget)

**Next Milestones:**
- Jul 22: Mapping specification draft complete (50% remaining)
- Jul 22–Aug 1: Implementation phase starts (coding)
- Aug 1–15: Sandbox integration testing
- Aug 15: Integration tests 80% complete (target)

**Note:** Integration team feedback: "Mapping is cleaner than expected. Ready to start coding soon."

---

### Q3-3: Advanced Observability Phase 2 — 28% COMPLETE

**Week 2 Deliverables:**
- ✅ Tempo production deployment (Jul 8, blue-green approach)
  - Deployment window: 8:00–10:00 AM UTC
  - Result: **SUCCESSFUL** ✅ Zero downtime
  - Trace ingestion: Live and operational
  - Storage: 30-day retention active
- ✅ OpenTelemetry collector configuration deployed
  - OTLP ingestion: Accepting traces on port 4317 ✅
  - Batching: 100 spans/batch, 10 second timeout ✅
  - Sampling rules active:
    - 100% error sampling: Working (all errors captured) ✅
    - 1% success sampling: Working (statistical sampling) ✅
    - 10% high-latency sampling: Working (>500ms traces) ✅
- ✅ Grafana dashboards prototype deployed
  - Service dependency graph: Preliminary topology visible (6 services, 12 interactions)
  - Trace detail dashboard: Sample traces displayed
  - Latency distribution: Percentile breakdown (p50, p95, p99)

**Production Deployment Results:**
```
Jul 8 Deployment Execution:
  8:00 AM UTC: Blue environment live + test traces flowing
  8:30 AM UTC: Green environment validates new traces
  9:00 AM UTC: Blue → Green traffic switch (all trace data continuous)
  9:30 AM UTC: Monitoring confirmed zero data loss
  10:00 AM UTC: Deployment complete, full production operational

Metrics (First 24 hours):
  - Trace ingestion rate: 2,847 traces/hour (avg)
  - OTLP API latency: p50=12ms, p95=45ms, p99=120ms ✅
  - Span batching efficiency: 98.2% of batches full
  - Trace cardinality: 156 unique services (including sidecar proxies)
  - Storage utilization: 2.3 GB/day (30-day budget: 69 GB) ✅
```

**Service Mesh Instrumentation (Starting):**
- Phase 1 targets: 3 critical backend services
- Instrumentation approach: OpenTelemetry Java SDK + sidecar injection
- Status: Implementation starting Jul 15
- Target: Phase 1 complete by Jul 22

**Effort Consumed:** 5 hours (of 18 hour budget)

**Next Milestones:**
- Jul 15–22: Service instrumentation phase 1 (3 services)
- Jul 22–Aug 1: Phase 2 (remaining 3 services)
- Aug 1: All services instrumented; dashboards production-ready
- Aug 19: Sampling rules validated; observability complete

---

### Q3-4: FDA Premarket Readiness Assessment — 35% COMPLETE

**Week 2 Deliverables:**
- ✅ Technical readiness phase 1 COMPLETE (IEC 62304)
  - Phase 1–2 repos: 100% classification verified ✅
  - Traceability: 100% of design decisions linked to requirements
  - Design controls: All critical paths verified
  - **Result: PASS** (exceeds ≥95% target)
- ✅ SBOM/VEX analysis started (phase 2)
  - Q2 backfill: 5 releases with SLSA v1 attestations ✅
  - Current releases: Automated SBOM generation in CI (since Q2-2) ✅
  - VEX documents: 3 draft VEX documents created (vulnerability mapping)
  - Vulnerability scan integration: In progress (scheduled complete Jul 22)
- ✅ Pre-FDA regulatory counsel consultation (Jul 15)
  - Meeting with 2 external FDA counsel firms
  - Assessment criteria reviewed and approved
  - Next steps: Formal engagement if GO decision on Aug 21

**FDA Assessment Timeline (Confirmed):**
- Jul 1–15: Phase 1 (IEC 62304) ✅ COMPLETE
- Jul 15–Aug 1: Phase 2 (SBOM/VEX, provenance)
- Aug 1–10: Phase 3 (cybersecurity assessment, SSDF v1.1)
- Aug 10–15: Phase 4 (regulatory & legal review)
- Aug 15–20: Phase 5 (final business case, pre-decision briefing)
- Aug 21, 2 PM UTC: **CRITICAL DECISION VOTE**

**Effort Consumed:** 5 hours (of 12 hour budget)

**Next Milestones:**
- Jul 22: SBOM/VEX analysis complete; provenanceVerification starts
- Aug 1: Phase 2 complete; cybersecurity assessment begins
- Aug 10: Regulatory alignment confirmed
- Aug 21: Formal GO/NO-GO decision

---

### Q3-5: Third-Party Dependency Audit — 0% (SCHEDULED START SEP 1)

**Status:** Preparations continuing (scheduled post-decision kickoff)

---

## Parallel Execution Efficiency

**Week 2 Effort Consumption:**
- Q3-1 (FMEA): 8 hours
- Q3-2 (EHR): 8 hours
- Q3-3 (Observability): 5 hours
- Q3-4 (FDA): 5 hours
- **Total:** 26 hours (of 74 hour Q3 budget = 35% through first 2 weeks)

**Pace:** 26 hours over 14 days = 1.86 h/day; on track for 74 hours by Sep 30 ✅

**Resource Utilization:** All teams mobilized; zero conflicts or bottlenecks.

---

## Compliance Score Trajectory

**Q2 Closure:** 88.8/100
**Q3 Week 2 Status:** 88.8/100 (scores locked in from Q2; waiting for Q3 initiative completion)

**Q3 Projected Contributions (Sep 30):**
- Q3-1 (FMEA): +0.5 points (risk management process formalized)
- Q3-2 (EHR): +0.3 points (clinical integration capability)
- Q3-3 (Observability): +0.2 points (production visibility)
- Q3-4 (FDA): Conditional on GO/NO-GO decision
- Q3-5 (Dependency): +0.2 points (dependency policy published)

**Projected Q3 Close:** 89.0–89.2/100 ✅ (target 89.0)

---

## Risk Assessment (Week 2)

### Critical Risks: NONE

All initiatives executing smoothly. Infrastructure stable.

### High-Risk Items (Monitoring)

| Risk | Status | Mitigation | Owner |
|------|--------|-----------|-------|
| Tempo trace volume growth | GREEN | Storage budget 69 GB/month; current 2.3 GB/day sustainable | Platform Eng |
| EHR integration complexity | GREEN | 3 of 5 resource types mapped; no scope surprises | Eng Lead |
| FMEA mitigation design | YELLOW | 8 mitigations drafted; verification approach TBD | Timothy H. |
| FDA assessment schedule | GREEN | Phase 1 complete on time; Phase 2 on track | Timothy H. |

---

## Key Accomplishments This Week

1. ✅ FMEA workshop completed; 18 hazard modes identified
2. ✅ Tempo production deployment successful; zero downtime
3. ✅ EHR mapping specification 50% complete; sandboxes validated
4. ✅ FDA technical assessment phase 1 complete
5. ✅ FDA regulatory counsel consultation conducted
6. ✅ All initiatives on schedule; no critical blockers

---

## Next Week Priorities (Jul 22–28)

1. **Q3-1 (FMEA):** Complete baseline documentation; prepare quarterly review schedule
2. **Q3-2 (EHR):** Complete mapping specification; start implementation
3. **Q3-3 (Observability):** Phase 2 service instrumentation; preliminary dashboards operational
4. **Q3-4 (FDA):** Complete SBOM/VEX analysis; start provenance verification
5. **Jul 28:** FMEA baseline frozen (input to FDA assessment)

---

## Conclusion

Q3 Week 2 checkpoint shows excellent progress across all initiatives. Key technical deliverables (FMEA workshop, Tempo deployment, EHR mapping) completed on schedule. FDA assessment tracking toward Aug 21 decision date. All teams mobilized and executing efficiently. No critical blockers identified.

**Status: ✅ ALL INITIATIVES GREEN — ON SCHEDULE FOR AUG 21 DECISION**

---

**Report Compiled By:** Timothy Hartzog, Compliance Officer  
**Date:** July 15, 2026

